BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension.
- DOI
- 10.1002/pul2.12063
- Published
- 2022 Apr
- Container
- Pulmonary circulation
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/pul2.12063,
title = {BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension.},
author = {Spikes LA and Bajwa AA and Burger CD and Desai SV and Eggert MS and El-Kersh KA and Fisher MR and Johri S and Joly JM and Mehta J and Palevsky HI and Ramani GV and Restrepo-Jaramillo R and Sahay S and Shah TG and Deng C and Miceli M and Smith P and Shapiro SM},
year = {2022},
journal = {Pulmonary circulation},
doi = {10.1002/pul2.12063},
url = {https://doi.org/10.1002/pul2.12063}
}RIS
TY - JOUR TI - BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension. AU - Spikes LA AU - Bajwa AA AU - Burger CD AU - Desai SV AU - Eggert MS AU - El-Kersh KA AU - Fisher MR AU - Johri S AU - Joly JM AU - Mehta J AU - Palevsky HI AU - Ramani GV AU - Restrepo-Jaramillo R AU - Sahay S AU - Shah TG AU - Deng C AU - Miceli M AU - Smith P AU - Shapiro SM PY - 2022 JO - Pulmonary circulation DO - 10.1002/pul2.12063 UR - https://doi.org/10.1002/pul2.12063 ER -
APA
LA, S., AA, B., CD, B., SV, D., MS, E., KA, E., MR, F., S, J., JM, J., J, M., HI, P., GV, R., R, R., S, S., TG, S., C, D., M, M., P, S., & SM, S. (2022). BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension.. Pulmonary circulation. https://doi.org/10.1002/pul2.12063
Source records
- pubmed · retrieved 2026-09-25T11:54:55.140Z